GLOBAL BLOOD THERAPEUTICS Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

GBT earnings call for the period ending December 31, 2021.

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2021 Results - Earnings Call Transcript

Global Blood Therapeutics press release (GBT): Q4 GAAP EPS of -$1.36 misses by $0.23.Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M.Cash, cash equivalents, and marketable…

Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is -$1.13

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close.

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial resu

The European Commission (EC) has approved Global Blood Therapeutics Inc''s (NASDAQ: GBT ) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). Oxbryta, a once-daily, oral … Full story available on Benzinga.com

Global Blood Therapeutics (GBT) Oxbryta was approved by the European Commission ((EC)) to treat hemolytic anemia due to sickle cell disease ((SCD)) in patients 12 years of age and older…

By Chris Wack Global Blood Therapeutics Inc. said Wednesday that the European Commission has granted Marketing Authorization for Oxbryta voxelotor for the…